Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by KalVista Pharmaceuticals, Inc. < Previous 1 2 3 4 Next > KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet February 10, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session February 07, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference February 03, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 02, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President January 05, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 04, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering December 27, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Second Fiscal Quarter Results December 08, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 05, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting November 14, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at Upcoming Investor Conferences November 07, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 02, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema October 31, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat October 19, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman October 17, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop October 07, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 05, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema October 04, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop September 30, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports First Fiscal Quarter Results September 08, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 02, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema August 23, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference July 19, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results July 07, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 05, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program July 05, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) June 23, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program June 08, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 03, 2022 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.